Table 1.
Clinical characteristics of VHL patients in China and UK
| Tumor | China (n = 300) | UK (n = 573)a | P c | ||||
|---|---|---|---|---|---|---|---|
| Affected N (%) | Not affected N (%) | Onset age (y) (Mean±SD) | Affected N (%) | Not affected N(%) | Onset age (y) (Mean) | ||
| CHB | 184 (61.3) | 116 (38.7) | 31.3 ± 11.9 | 470 (82) | 103 (18) | 30.9 | <0.001 |
| RCC | 128 (42.7) | 172 (57.3) | 40.2 ± 11.2 | 201 (35) | 372 (65) | 39.7 | 0.028 |
| PCT | 140 (46.7) | 160 (53.3) | 36.1 ± 11.4 | ‐b | ‐b | ‐b | ‐b |
| PHEO | 39 (13.0) | 261 (87.0) | 33.7 ± 13.1 | 115 (20) | 458 (80) | 24.0 | 0.009 |
| RA | 67 (22.3) | 233 (77.7) | 28.5 ± 12.6 | 418 (73) | 155 (27) | 25.0 | <0.001 |
CHB, central nervous system hemangioblastoma; RA, retinal angioma; RCC, renal cell carcinoma; PCT, pancreatic cyst or pancreatic tumor; PHEO, pheochromocytoma.
a
Ong et al 8.
b
Not described in the UK cohort.
c
P value for the difference of overall penetrance in VHL patients between China and UK.